The Annals Visit the journal of Pharmacy Technology for more pharmacy practice research and reviews!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 12, pp. 1825-1830. DOI 10.1345/aph.1D262
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stanford, B. L
Right arrow Articles by Zondor, S. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanford, B. L
Right arrow Articles by Zondor, S. D

NEW DRUG APPROVALS

Bortezomib Treatment for Multiple Myeloma

Brad L Stanford, PharmD BCOP

Assistant Professor of Pharmacy Practice — Oncology, School of Pharmacy, Texas Tech Health Sciences Center, Lubbock, TX

Stacey D Zondor, PharmD

Pharmacy Practice Resident, School of Pharmacy, Texas Tech Health Sciences Center

Reprints: Brad L Stanford PharmD BCOP, School of Pharmacy, Texas Tech Health Sciences Center, 3601 4th St., MS 8162, Lubbock, TX 79430-8162, FAX 806/743-4209, brad.stanford{at}ttuhsc.edu

OBJECTIVE: To review the pharmacology, pharmacokinetics, and place of bortezomib in the therapy of multiple myeloma (MM).

DATA SOURCES: A MEDLINE search was conducted (1985–May 2003). Meeting abstracts, bibliographies from identified articles, and the package insert were also used. Search terms were bortezomib, multiple myeloma, Velcade, PS-341, LDP-341, MLNM341, and proteasome inhibitor.

STUDY SELECTION AND DATA EXTRACTION: All published information relevant to the clinical activity of bortezomib in MM was considered. All human clinical studies, with an emphasis on Phase II trials, were selected.

DATA SYNTHESIS: Current therapy for MM yields significant, although temporary, responses. Bortezomib is a novel anticancer agent with significant activity in relapsed and refractory MM.

CONCLUSIONS: Although the clinical trial data are incomplete, bortezomib offers a novel therapeutic modality for patients with MM who would otherwise have few options.

Key Words: bortezomib, LDP-341, MLNM341, multiple myeloma, proteasome inhibitor, PS-341, Velcade

Published Online, October 29, 2003. www.theannals.com, DOI 10.1345/aph.1D262

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-03-038-H01


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
T. A. Luster, J. A. Carrell, K. McCormick, D. Sun, and R. Humphreys
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
Mol. Cancer Ther., February 1, 2009; 8(2): 292 - 302.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
J. A. Poff, C. T. Allen, B. Traughber, A. Colunga, J. Xie, Z. Chen, B. J. Wood, C. Van Waes, K. C. P. Li, and V. Frenkel
Pulsed High-Intensity Focused Ultrasound Enhances Apoptosis and Growth Inhibition of Squamous Cell Carcinoma Xenografts with Proteasome Inhibitor Bortezomib
Radiology, August 1, 2008; 248(2): 485 - 491.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
C. M. Bailey, D. E. Abbott, N. V. Margaryan, Z. Khalkhali-Ellis, and M. J. C. Hendrix
Interferon Regulatory Factor 6 Promotes Cell Cycle Arrest and Is Regulated by the Proteasome in a Cell Cycle-Dependent Manner
Mol. Cell. Biol., April 1, 2008; 28(7): 2235 - 2243.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. C. Attar, D. J. DeAngelo, J. G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K. K. Ballen, S. McAfee, K. B. Miller, et al.
Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
Clin. Cancer Res., March 1, 2008; 14(5): 1446 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Shi, G. J. Tricot, T. K. Garg, P. A. Malaviarachchi, S. M. Szmania, R. E. Kellum, B. Storrie, A. Mulder, J. D. Shaughnessy Jr, B. Barlogie, et al.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
Blood, February 1, 2008; 111(3): 1309 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Koschny, H. Holland, J. Sykora, T. L. Haas, M. R. Sprick, T. M. Ganten, W. Krupp, M. Bauer, P. Ahnert, J. Meixensberger, et al.
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis
Clin. Cancer Res., June 1, 2007; 13(11): 3403 - 3412.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. R. Chade, J. Herrmann, X. Zhu, J. D. Krier, A. Lerman, and L. O. Lerman
Effects of Proteasome Inhibition on the Kidney in Experimental Hypercholesterolemia
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1005 - 1012.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.